Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06319820 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
A Phase 3 study of Non-Muscle Invasive Bladder Neoplasms, sponsored by Janssen Research & Development.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 641
- Enrollment target
- 20
- Study locations
NCT06319820: Recruiting Phase 3 study of Non-Muscle Invasive Bladder Neoplasms, sponsored by Janssen Research & Development.
NCT06319820 is a Phase 3 study of Non-Muscle Invasive Bladder Neoplasms that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 641 participants, above the 207-participant average among 6 other Non-Muscle Invasive Bladder Neoplasms trials with a reported enrollment target (210% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06319820, a Phase 3 study of Non-Muscle Invasive Bladder Neoplasms, is actively recruiting participants, sponsored by Janssen Research & Development.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 641 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of intermediate-risk NMIBC.
Primary Outcome
DFS is measured as the time from randomization to the date of the first documented recurrence of Ta non-muscle invasive bladder cancer (NMIBC) of any grade, disease progression, or death due to any cause, whichever occurs first.
Conditions Studied
Interventions
- DRUG Gemcitabine
- COMBINATION_PRODUCT TAR-210
- DRUG MMC
Study Locations (20)
California
- Genesis Research LLC - Los Alamitos
- USC Norris Comprehensive Cancer Center - Los Angeles
- University of California Irvine Medical Center - Orange
- Om Research LLC - San Diego
- Genesis Research LLC - Sherman Oaks
Colorado
- University of Colorado Cancer Center Anschultz Cancer Pavilion - Aurora
- Colorado Clinical Research - Lakewood
Michigan
- Karmanos Cancer Institute - Detroit
- Comprehensive Urology - Royal Oak
Missouri
- Mercy Research - St Louis
- Specialty Clinical Research of St Louis - St Louis
Arkansas
- Arkansas Urology - Little Rock
Florida
- Moffitt Cancer Center - Tampa
Illinois
- Northwestern University - Chicago
Indiana
- First Urology - Jeffersonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 641 participants |
| Start Date | 2024-04-18 |
| Est. Completion | 2032-12-31 |
| Phase | Phase 3 |
What NCT06319820 shows while recruiting
NCT06319820 is an interventional study that assigns participants to a tested intervention. The registered 641 participants enrollment target is mid-sized for trials with a published cap, above the 207-participant average among 6 other Non-Muscle Invasive Bladder Neoplasms trials with a reported enrollment target (210% higher).
The record links to 1 condition, with Non-Muscle Invasive Bladder Neoplasms appearing as the primary indexed condition, and to 3 interventions - of which Gemcitabine is the first listed.
NCT06319820 names 20 study sites across 13 states, led by California, Colorado, Michigan.
Frequently Asked Questions
What is clinical trial NCT06319820 about?
NCT06319820 is a clinical study titled "A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer". The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of intermediate-risk NMIBC.
What is the current status of trial NCT06319820?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 641 participants. The study started on 2024-04-18. Estimated completion is 2032-12-31.
What conditions does trial NCT06319820 study?
This clinical trial studies the following conditions: Non-Muscle Invasive Bladder Neoplasms.
What interventions are being tested in trial NCT06319820?
The interventions under investigation include: Gemcitabine (DRUG), TAR-210 (COMBINATION_PRODUCT), MMC (DRUG).
Who is sponsoring clinical trial NCT06319820?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06319820 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Muscle Invasive Bladder Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
RECRUITING · Phase 3
-
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
ACTIVE NOT RECRUITING · Phase 3
-
A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer
RECRUITING · Phase 1
-
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
RECRUITING · Phase 2
-
A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States
RECRUITING
-
Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06625060 · 641 participants · Phase 2
A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults
- NCT05204888 · 642 participants · NA
myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home
- NCT04339699 · 640 participants · NA
NobleStitch EL STITCH Trial is a PFO Comparative Trial
- NCT04979338 · 640 participants · Phase 3
Development of Effective, Opioid Sparing Techniques for Peri-operative Pain Management of Transgender Patients Undergoing Gender Affirming Surgeries
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI